Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
IPO Year:
Exchange: NASDAQ
Website: titanpharm.com
NT 10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
425 - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
NT 10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
RW - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00
SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4/A - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4/A - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4/A - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
4 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE"). The Merger Agreement was approved by Titan's board of directors (the "Board"). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing"), Titan will be combined with KE in a "reverse merger" transaction consisting
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed. About Titan Pharmaceuticals Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with utilizing ProNeura® long-term, conti
SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Amendment"). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 20
SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut
SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the "Purchase Agreement") with The Sire Group Ltd. ("Sire Group") for the sale of the Company's newly designated Series AA Convertible Preferred Stock (the "Preferred Stock"). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory note from Sire Group, personally guaranteed by a principal of Sire Group, due and payable on September 23, 2023, subje
SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the "Agreement") with Fedson, Inc., a Delaware Corporation ("Fedson"), for the sale of certain ProNeura assets including Titan's portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology. The Company's addiction portfolio consists of the Probuphine and Nalmefene implant programs. Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing
Signs Non-Binding Letter of Intent for Transformational TransactionContinues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to complete a reverse merger with a leading developer in Advanced Air Mobility (AAM) (the "Proposed Reverse Merger"). Titan Chief Executive Officer, David E. Lazar, commented, "We believe that the Advanced Air Mobility sector offers a potential tremendous growth opportunity for our shareholders. I am encouraged by our recent advancements
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix Inc. ("Ocular") pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States. Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones. Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan Pharmaceuticals, commented, "We are pleased to enter into this licensing agreement with Ocular. Our team has been
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Board") from five (5) to eleven (11) and appointed six new directors following their election at its special meeting of stockholders held on August 15, 2022 (the "Special Meeting"). The new directors, which were on a nominee slate proposed by Activist Investing LLC (together with its affiliates, "Activist Investing"), are Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo and David Natan. In addition, following the Special Meeting, Mr. Lazar was appointed interim Cha
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, "Activist Investing" or "we"), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") with 25.2% of the Company's outstanding shares, today issued the following statement: "We have submitted a request for the Company to hold a special meeting of the Company's stockholders (the "Special Meeting") to expand the size of Titan's Board of Directors (the "Board") by six (6) directors and to elect our slate of six (6) highly qualified professionals, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E.
Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million. Outset Medical (NASDAQ:OM) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million. Chemomab Therapeutics (NASDAQ:CMMB) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million. Titan Pharma (NASDAQ:TTNP) shares moved u
Gainers Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. Syra Health (NASDAQ:SYRA) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. Titan Pha
Gainers Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. Galera Therapeutics (NASDAQ:GRTX) stock increased by 9.13% to $0.2. The market value of their outstanding shares is at $10.9 million. Innovative Eyewear (NASDAQ:LUCY) shares increased by 8.54% to $0.26. The company's market cap stands at $3.4 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock moved upwards by 6.7% to $0.34. Calidi Biotherapeutics (AMEX:CLDI) shares increased by 6.17% to $0.17. The market value of their outstanding shares is at $8.4 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares increased
Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ:AGEN) declined 17% to $0.4181 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Auddia Inc. (NASDAQ:AUUD) shares jumped 231.7% to $4.72 after the company announced the USPTO awarded it with U.S. Patent 11,935,520 for the core AI technology the company uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers. Longeveron Inc. (NASDAQ:LGVN) shares climbed 93.2% to $4.2499 after the company submitted paperwork for a share offering. UTime Limited (NASDAQ:WTO) gained
- SEC 13D/Amended Filing After giving effect to these changes in membership, as of April 2, 2024, four of the board's seven directors had been nominated by the reporting persons. The reporting persons expect to propose to the Issuer a business combination with KE Sdn. Bhd., a Malaysian company. Any such transaction would be subject to execution of definitive documents negotiated between the reporting persons and a committee of independent directors of the Issuer. This report does not constitute an offer of any securities for sale.
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday. Athira Pharma (NASDAQ:ATHA) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million. Clearside Biomedical (NASDAQ:CLSD) stock rose 4.79% to $1.75. The company's market cap stands at $1
Gainers Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. Coeptis Therapeutics (NASDAQ:COEP) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. Titan Pharma (NASDAQ:TTNP) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. Iridex (NASDAQ:IRIX) stock in
Gainers Fresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 29.0% to $1.29. The company's market cap stands at $141.3 million. ChromaDex (NASDAQ:CDXC) stock moved upwards by 27.91% to $3.07. The company's market cap stands at $231.1 million. Elicio Therapeutics (NASDAQ:ELTX) stock moved upwards by 24.0% to $6.2. The market value of their outstanding shares is at $59.5 million. Immuneering (NASDAQ:IMRX) stock increased by 23.04% to $2.35. The company's market cap stands at $68.8 million. Biotricity (NASDAQ:BTCY) stock rose 21.08% to $